Recurrent Diffuse Intrinsic Pontine Glioma
7 clinical trials · Condition
◉ Watch Recurrent Diffuse Intrinsic Pontine Glioma
| Record | Firm | Date |
|---|---|---|
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944) | Children's Oncology Group | 2022-01-28 |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas (NCT05009992) | University of California, San Francisco | 2021-10-20 |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors (NCT03598244) | National Cancer Institute (NCI) | 2018-11-27 |
| Hypofractionated Radiotherapy for Recurrent DIPG (NCT03841435) | University of Cincinnati | 2018-01-31 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors (NCT03387020) | Pediatric Brain Tumor Consortium | 2018-01-13 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (NCT02359565) | National Cancer Institute (NCI) | 2015-06-03 |
Track Recurrent Diffuse Intrinsic Pontine Glioma automatically
Every clearance here is in the API, with alerts when new ones post.